For the Inventor, By the Inventor

Enter assignee name

Adherex Technologies, Inc.

USPTO Granted Patents = 31

% Expired Patents = 29.0

Forward Citations = 301

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Orest W Blaschuk (29 out of 49 patents)

Barbara J Gour (26 out of 45 patents)

James Matthew Symonds (17 out of 17 patents)

4. Stephen Byers (8 out of 8 patents)

5. Stephanie Denise Michaud (4 out of 4 patents)

6. Patrick Doherty (3 out of 3 patents)

7. Feng Ni (2 out of 8 patents)

8. Zhigang Chen (2 out of 8 patents)

9. Thomas Spector (2 out of 14 patents)

10. Anmar Ali (2 out of 5 patents)

11. Zenjian Hu (2 out of 2 patents)

12. Donald W Kufe (1 out of 61 patents)

13. Shaomeng Wang (1 out of 81 patents)

14. William Paul Peters (1 out of 1 patent)

15. Brian Huber (1 out of 7 patents)

Core Competencies:

Neurotoxicity

DPD Inhibitors

5-FU Prodrugs

Cadherin Modulation

Peptidomimetics

Cell Adhesion

Cancer Metastasis

Gene Expression

Tissue Permeability

Diagnosis

Antibodies

31 patents: Sort by Forward Citations

1. 8658618 - Methods for preventing or reducing neurotoxicity associated with administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs (2014-02-25),

2. 8318756 - Methods for administering DPD inhibitors in combination with 5-FU and 5-FU prodrugs (2012-11-27),

3. 7481999 - Compounds and methods for modulating OB-cadherin-mediated function (2009-01-27),

4. 7476509 - Compounds and methods for modulating functions of nonclassical cadherins (2009-01-13),

5. 7456153 - Compounds and methods for modulating functions of classical cadherins (2008-11-25),

6. 7446120 - Peptidomimetic modulators of cell adhesion (2008-11-04),

7. 7268115 - Peptidomimetic modulators of cell adhesion (2007-09-11),

8. 7122623 - Compounds and methods for modulating cell adhesion (2006-10-17),

9. 6962969 - Compounds and methods for modulating nonclassical cadherin-mediated functions (2005-11-08),

10. 6830894 - Compounds and methods for modulating claudin-mediated functions (2004-12-14),

11. 6806255 - Compounds and methods for modulating adhesion molecule function (2004-10-19),

12. 6797807 - Compounds and methods for cancer therapy (2004-09-28),

13. 6756356 - Compounds and methods for modulating claudin-mediated functions (2004-06-29),

14. 6723700 - Compounds and methods for modulating claudin-mediated functions (2004-04-20),

15. 6706685 - Compounds and methods for stimulating &bgr;-catenin mediated gene expression and differentiation (2004-03-16),

Company Overview

Adherex Technologies, Inc. is a biopharmaceutical company based in Ottawa, Canada, focused on developing innovative therapies for cancer treatment. The company specializes in drug delivery systems and targeted therapies that enhance the efficacy and safety of existing treatments. By leveraging advanced research in oncology, Adherex aims to improve patient outcomes through its proprietary technologies, addressing unmet medical needs in the field of cancer care.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

31 Patents

#32 in Ottawa

#443 in Canada

#21,284 in the World

Adherex Technologies, Inc.

Forward Citations = 301

17 inventors:

Orest W Blaschuk (29 out of 49 patents)

Barbara J Gour (26 out of 45 patents)

James Matthew Symonds (17 out of 17 patents)

4. Stephen Byers (8 out of 8 patents)

5. Stephanie Denise Michaud (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Adherex Technologies, Inc.. Retrieved from https://idiyas.com/company/adherex-technologies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…